Impact of plasmapheresis on disopyramide elimination

Pediatric Nephrology

Volumn 13, Issue 4, 1999, Pages 323-325

  Martin, Sherri Garcia ^a   Kearns, Gregory L ^a,b,c   Brod, Michael ^c   Austin, Gloria ^c   Vaughan, Bradley C ^a,c  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

Disopyramide; Extracorporeal drug removal; Pharmacokinetics; Plasmapheresis

Indexed keywords

DISOPYRAMIDE; OROSOMUCOID;

ADOLESCENT; ARTICLE; CASE REPORT; DRUG ELIMINATION; FEMALE; HEART ARRHYTHMIA; HUMAN; ORAL DRUG ADMINISTRATION; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN BINDING; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ANTI-ARRHYTHMIA AGENTS; DISOPYRAMIDE; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PLASMAPHERESIS;

EID: 0033020223     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004670050618     Document Type: Article

References (13)

1. Jones JV, Robinson MF, Parciany RK, Layfer LF, McLeod B (1981) Therapeutic plasmapharesis in systemic lupus erythematosis: effect on immune complexes and antibodies to DNA. Arthritis Rheum 24:1113-1120
2. Raghow G, Meyer MC, Straughn AB (1985) Determination of free disopyramide plasma concentrations using ultrafiltration and enzyme multiplied immunoassay. Ther Drug Monit 7: 466-471
3. Lima JJ, Shields BJ, Howell LH, MacKichan JJ (1984) Evaluation of fluorescence immunoassay for total and unbound serum concentrations of disopyramide. Ther Drug Med 6: 203-210
4. David BM, Tjokrosetio R, Ilett KF (1983) Plasma protein binding of disopyramide by equilibrium dialysis and ultrafiltration. Ther Drug Monit 5:81-86
5. Dollery SC (1991) Disopyramide. In: Boobis AR, Burley D, Davies DM et al. (eds) Therapeutic drugs. Churchill Livingstone, New York, pp 180-184
6. Lima JL (1986) Disopyramide. In: Evans WE, Schentag JJ, Jusko WJ (eds) Applied pharmacokinetics, 2nd edn. Applied Therapeutics, Spokane, pp 1210-1253
7. Karim A, Nissen C, Azarnoff DL (1982) Clinical pharmacokinetics of disopyramide. J Pharmacokinet Biopharm 10: 465-494
8. Burk M, Peters U (1983) Disopyramide kinetics in renal impairment: determinants of interindividual variability. Clin Pharmacol Ther 34:331-340
9. Svensson CK, Woodruff MN, Lalka D (1986) Influence of protein binding and use of unbound (free drug) concentrations. In: Evans WE, Schentag JJ, Jusko WJ (eds) Applied pharmacokinetics: principles of therapeutic drug monitoring, 2nd edn. Applied Therapeutics, Spokane, pp 187-219
10. Haughey DB, Kraft CJ, Matzke GR, Keane WF, Halstenson CE (1985) Protein binding of disopyramide and elevated α-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant patients. Am J Nephrol 5: 35-39
11. Sevka MJ, Matthews SJ, Nightingale CH, Izard MW, Fieldman A, Chow MSS (1981) Disopyramide hemodialysis and kinetics in patients requiring long-term hemodialysis. Clin Pharmacol Ther 29:322-326
12. Gilcher RO (1996) Apheresis: principles and practices. Rossi EC, Simon TL, Moss GS, Gould SA (eds) Principles of transfusion medicine, 2nd edn. Williams and Wilkins, Baltimore, pp 537-546
13. Liu E, Rubenstein M (1982) Phenytoin removal by plasmapheresis in thrombotic thrombocytopenic purpura. Clin Pharmacol Ther 31:762-765